Obesity Drugs and Cancer Innovations

This chapter explores the testing of obesity drugs, particularly liraglitide in children, addressing concerns about long-term health effects and ethical implications. It also highlights a new cancer treatment, Ivonesimab, which has shown promising results compared to Merck's Keytruda, marking a significant advance in lung cancer therapies. The discussion emphasizes the complexities of these medical developments and their broader societal impacts.